Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00245128 · ClinicalTrials.gov registry record · Phase 2
Imatinib Mesylate in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by OHSU Knight Cancer Institute.
- Terminated
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00245128 is a Phase 2 study that was terminated before completion, run by OHSU Knight Cancer Institute. The registered enrollment target is 10 participants.
The verdict
NCT00245128, a Phase 2 study, was terminated before completion, sponsored by OHSU Knight Cancer Institute.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in treating patients with myelofibrosis.
Interventions
- DRUG imatinib mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2005-08 |
| Est. Completion | 2011-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00245128
The ClinicalTrials.gov registry entry for NCT00245128 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which imatinib mesylate is the first listed.
NCT00245128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00245128 about?
NCT00245128 is a clinical study titled "Imatinib Mesylate in Treating Patients With Myelofibrosis". RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and how well it works in treating patients with myelofibrosis.
What is the current status of trial NCT00245128?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2005-08. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00245128?
The interventions under investigation include: imatinib mesylate (DRUG).
Who is sponsoring clinical trial NCT00245128?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.